Icotinib-associated focal proliferative IgA nephropathy and acute renal tubule injury
10.3760/cma.j.cn114015-20211105-01136
- VernacularTitle:埃克替尼相关局灶增生型IgA肾病和急性肾小管损伤
- Author:
Yongli LIANG
1
;
Lixin ZHANG
;
Hongxin YANG
;
Zhao TAN
;
Xiaobin GUO
;
Lin LIU
Author Information
1. 内蒙古自治区人民医院药学处，呼和浩特 010017
- Publication Type:Journal Article
- Keywords:
Protein-tyrosine kinases;
Nephrosis;
Icotinib
- From:
Adverse Drug Reactions Journal
2023;25(2):112-114
- CountryChina
- Language:Chinese
-
Abstract:
A 68-year-old male patient with lung adenocarcinoma was treated with icotinib 125 mg thrice daily orally and Kanglaite soft capsules (康莱特软胶囊) 2.7 g orally 4 times daily. The patient′s serum creatinine (Scr) was 91 μmol/L before the medication. He developed foamy urine, fatigue, chest tightness, loss of appetite, and red rash on the neck and chest skin 29 days after the medication. No intervention was given and the patient received a total of 76 days of medication. Laboratory tests showed Scr 167 μmol/L, immunoglobulin A (IgA) 4 090 mg/L, urine protein 2 g/L, urinary protein 2.61 g per 24 hours, urinary red blood cells 6.8/high power field, and urine α microglobulin 66.9 mg/L. Through pathological examination, the patient was diagnosed with focal proliferative IgA nephropathy and acute renal tubule injury, which was considered to be related to icotinib. Low protein diet and the symptomatic treatments were given.After 80 days of treatment, the patient′s Scr was 189 μmol/L and urine protein was 2 g/L. After that, the patient was lost to follow-up.
